Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
National Institutes of Health (NIH)
Funding duration: Up to 5 years, with R61 phase lasting 1-2 years and R33 phase lasting up to 3 years.
To support innovative mechanistic research to accelerate the development of effective precision probiotic interventions.
Higher education institutions, nonprofits, governmental organizations, and researchers.
Beneficiaries include patients benefiting from improved probiotic therapies.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments, and tribal governments.
Non-domestic (non-U.S.) entities are not eligible to apply.
Applications must be from U.S.-based organizations; non-domestic components of U.S. organizations are not eligible.
Projects must focus on mechanistic research related to precision probiotic therapies.
The R61 phase should identify host biological patterns affecting probiotic responses, while the R33 phase should assess causality in mechanistic studies.
The budget for both R61 and R33 phases should not exceed $350,000 in direct costs per year.
Application due date: June 2, 2027.
The R61 phase should be completed within 20 months post-award.
Applications must provide clear milestones for transitioning from R61 to R33 phases.
Applications must include a Milestones and R61-to-R33 Transition Criteria Plan.
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Applications will undergo scientific peer review and receive a written critique.
Applications that demonstrate a clear path to transition from R61 to R33 will be prioritized.
The grant supports both observational studies and mechanistic trials.
Transition from R61 to R33 is not guaranteed and requires administrative review.
Projects should align with NIH's mission and priorities in health research.
Applications that address variability in probiotic responses will have a competitive edge.
Clear definition of milestones and transition criteria.
Failure to comply with application instructions may lead to rejection.
Engage with NIH contacts early to ensure alignment with funding priorities.
Highlight innovative approaches to precision probiotics in applications.